Evidence map›Paper›PMID 36789895›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2023

Impact of National Institutes of Health and Food and Drug Administration Tobacco Research Funding: A Bibliometrics Analyses.

Kriti Sharma, Jonathan Moyer, Charlene Liggins, Mary Garcia-Cazarin, Rachel J Mandal, Kay L Wanke, Helen I Meissner

Abstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Examining Tobacco-Related Social Media Research in Government Policy Documents: Systematic Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kriti SharmaOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Jonathan MoyerOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Charlene LigginsOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Mary Garcia-CazarinOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Rachel J MandalOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Kay L WankeOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.
Helen I MeissnerOffice of Disease Prevention, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-7172-4677

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionConduct bibliometric analyses documenting the output of National Institutes of Health (NIH) tobacco-related and Food and Drug Administration (FDA) tobacco regulatory science (FDA-TRS) research portfolios. AIMS AND

methodsPubMed identifiers for publications between 2015 and 2020 citing tobacco funding by NIH and/or FDA were imported into NIH iCite generating measures of productivity and influence, including number of citations, journal, relative citation ratios (RCR), and comparison of research influence across Web of Science (WoS) disciplines. Coauthorship and measures of centrality among and between NIH and FDA-supported investigators gauged collaboration.

resultsBetween FY 2015 and 2020, 8160 publications cited funding from NIH tobacco-related grants, 1776 cited FDA-TRS grants and 496 cited Common funding (ie, both NIH and FDA-TRS funding). The proportion of publications citing NIH grants declined while those citing FDA-TRS or Common funding rose significantly. Publications citing Common funding showed the highest influence (mean RCR = 2.52). Publications citing FDA-TRS funding displayed higher median RCRs than publications citing NIH funding in most WoS categories. Higher translational progress was estimated over time for FDA-TRS and Common publications compared to NIH publications. Authors citing Common funding scored highest across all collaboration measures.

conclusionsThis study demonstrates the high bibliometric output of tobacco research overall. The rise in publications citing FDA-TRS and Common likely reflects increased funding for TRS research. Higher RCRs across WoS subject categories and trends towards human translation among FDA-TRS and Common publications indicate focus on research to inform regulation. This analysis suggests that FDA support for TRS has expanded the field of tobacco control resulting in sustained productivity, influence, and collaboration. IMPLICATIONS: This paper is the first effort to better describe the impact of tobacco research resulting from the addition of FDA funding for TRS in the past decade. The analysis provides impetus for further investigation into the publication topics and their focus which would offer insight into the specific evidence generated on tobacco control and regulation.

Indexed as

BibliometricsTobacco ProductsEfficiencyHumansNational Institutes of Health (U.S.)Tobacco ControlUnited StatesUnited States Food and Drug Administration

Identifiers

PMID36789895
PMCPMC10202643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.